Tag: 200-300

On January 12, 2018, Wang, Fang; Li, Chong; Zhang, Zhaochao; Zhang, Xiaoqing published a patent.Computed Properties of 160377-42-4 The title of the patent was Organic compound based on triazine and quinoxaline and its application in organic light-emitting device. And the patent contained the following:

The invention relates to organic compound based on triazine and quinoxaline and its application in organic light-emitting device. The inventive organic compound has high glass transition temperature and mol. thermal stability, has low light absorption and high refractive index in visible light field, and can effectively improve light extraction efficiency of OLED device when applied in CPL layer of OLED device. The inventive compound has deep HOMO level and a high electron mobility, can be applied as hole blocking/electron transporting layer material of OLED device, and can effectively block transportation of hole or energy from light-emitting layer to the side of electron layer, thereby improving recombination efficiency of holes and electrons in light-emitting layer and improving light-emitting efficiency and service life of OLED device. The experimental process involved the reaction of 5-(4-Bromophenyl)pyrimidine(cas: 160377-42-4).Computed Properties of 160377-42-4

The Article related to triazine quinoxaline preparation oled, Heterocyclic Compounds (More Than One Hetero Atom): Triazines and other aspects.Computed Properties of 160377-42-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On December 23, 2021, Arasappan, Ashok; Bell, Ian M.; Bungard, Christopher James; Burgey, Christopher S.; Cox, Jason M.; Kelly, Michael J., III; Layton, Mark E.; Liu, Hong; Liu, Jian; Perkins, James J.; Shah, Akshay A.; Vanheyst, Michael David; Wu, Zhe published a patent.Safety of 2,5-Dichloro-4-(trifluoromethyl)pyrimidine The title of the patent was 2-Oxoimidazolidine-4-carboxamides as NaV1.8 inhibitors and their preparation. And the patent contained the following:

Compounds of formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders. Compounds of formula I wherein one of A and B is (un)substituted aryl and (un)substituted heteroaryl, and the other one of A and B is (un)substituted aryl, (un)substituted heteroaryl, (un)substituted C1-6 alkyl-aryl, (un)substituted C3-8 cycloalkyl-aryl, etc.; R1, R2, R3 and R4 are independently H, (un)substituted C1-6 alkyl, (un)substituted C3-6 alkenyl, (un)substituted C3-6 alkynyl, (un)substituted C3-10 cycloalkyl, etc.; R5 is H and (un)substituted C1-6 alkyl; R6 is H, (un)substituted C1-6 alkyl, (un)substituted C3-6 cycloalkyl and (un)substituted C2-6 cycloheteroalkyl; R7 is H, (un)substituted C1-6 alkyl, (un)substituted C2-6 alkenyl and (un)substituted C2-6 alkynyl; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their NaV1.8 inhibitory activity (data given). The experimental process involved the reaction of 2,5-Dichloro-4-(trifluoromethyl)pyrimidine(cas: 785777-98-2).Safety of 2,5-Dichloro-4-(trifluoromethyl)pyrimidine

The Article related to oxoimidazolidinecarboxamide preparation sodium channel inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Safety of 2,5-Dichloro-4-(trifluoromethyl)pyrimidine

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On September 26, 2013, Chan, Bryan; Estrada, Anthony; Shore, Daniel; Sweeney, Zachary published a patent.Recommanded Product: 4-(2-Bromopyrimidin-4-yl)morpholine The title of the patent was Preparation of pyrazolopyridines for treatment of Parkinsons disease. And the patent contained the following:

The title compounds I or II [R1 = (un)substituted alkyl, monocyclic heterocycloalkyl, bicyclic heterocycloalkyl, cycloalkyl; for I: 1-3 of X1-X4 = N, and the remainder are each CR2; for II: X4 = C or N, and 1-2 of X1-X3 = N and NR8, and the remainder = CR2, such that X1-X4 and N form a heteroaryl; R2 = H, alkyl, CN, halo, etc.; R8 = H, (un)substituted alkyl; with the proviso], useful for the prevention or treatment of a disorder caused by, associated with or accompanied by abnormal kinase activity, preferably abnormal LRRK2 activity, were prepared E.g., a multi-step synthesis of III, starting from 4-chloro-3-iodo-1H-pyrazolo[4,3-c]pyridine, was described. Exemplified compounds I and II were tested for their LRRK2 activity (data given). Pharmaceutical compositions comprising compound I or II, alone or in combination with other therapeutic agent, were disclosed. The experimental process involved the reaction of 4-(2-Bromopyrimidin-4-yl)morpholine(cas: 1209459-32-4).Recommanded Product: 4-(2-Bromopyrimidin-4-yl)morpholine

The Article related to pyrazolopyridine preparation lrrk2 inhibitor antiparkinsonian combination chemotherapy, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Recommanded Product: 4-(2-Bromopyrimidin-4-yl)morpholine

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On October 6, 2016, Jones, Alison; Kemp, Mark; Stockley, Martin; Gibson, Karl; Whitlock, Gavin published a patent.Category: pyrimidines The title of the patent was 1-Cyanopyrrolidine compounds as USP30 inhibitors and their preparation. And the patent contained the following:

The invention relates to compounds of formula I and method for the manufacture of inhibitors of deubiquitylating enzymes. In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of formula I wherein Z is absent and CR6R7; Y is a bond, C0-3 alkylene-NR11-C0-3 alkylene and (un)substituted C1-3 alkylene; R1, R6, R7 and R8 are independently H, F, CN, OH, (un)substituted C1-3 alkyl and (un)substituted C1-3 alkoxy; R2 is H, (un)substituted C1-6 alkyl, (un)substituted C1-6 alkoxy, (un)substituted 4- to 10-membered heteroaryl, etc.; R3, R4 and R5 are independently (un)substituted alkyl and (un)substituted C1-3 alkoxy; R9 is H, CN, OH, (un)substituted C1-6 alkyl, etc.; R10 is H, (un)substituted C1-6 alkyl; R11 is H, (un)substituted C1-6 alkyl, 4- to 10-membered heteroaryl, heterocyclyl, aryl, etc.; R9R10 can be taken together to form (un)substituted heterocyclic ring; R10R11 can be taken together to form (un)substituted (mono/bi)cyclic ring; R12 is (un)substituted (mono/bi/tri)cyclic 3- to 14-membered heteroaryl, heterocyclyl, cycloalkyl and aryl; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by amidation of 5-phenylpyridine-2-carboxylic acid with (R)-3-amino-1-(tert-butoxycarbonyl)pyrrolidine; the resulting tert-Bu (R)-3-(5-phenylpicolinamido)pyrrolidine-1-carboxylate underwent hydrolysis to give (R)-5-phenyl-N-(pyrrolidin-3-yl)picolinamide TFA, which underwent cyanation to give compound II. The invention compounds were evaluated for their USP30 inhibitory activity (data given). The experimental process involved the reaction of 5-Phenylpyrimidine-2-carboxylic acid(cas: 85386-20-5).Category: pyrimidines

The Article related to cyanopyrrolidine preparation usp30 inhibitor, Heterocyclic Compounds (One Hetero Atom): Pyrroles and Pyrrolizines and other aspects.Category: pyrimidines

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On August 5, 2021, Saulnier, Mark George; Chen, Jesse Jingyang; Karra, Srinivasa; Sprott, Kevin Tyler; Wiles, Jason Allan; Ray, Soumya published a patent.SDS of cas: 785777-98-2 The title of the patent was ASGPR-binding compounds for the degradation of extracellular proteins. And the patent contained the following:

Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described. The experimental process involved the reaction of 2,5-Dichloro-4-(trifluoromethyl)pyrimidine(cas: 785777-98-2).SDS of cas: 785777-98-2

The Article related to asgpr ligand preparation extracellular protein degradation disease therapy, Pharmacology: Effects Of Inflammation Inhibitors and Immune Agents and other aspects.SDS of cas: 785777-98-2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On May 25, 2018, Woodring, Jennifer L.; Bachovchin, Kelly A.; Brady, Kimberly G.; Gallerstein, Mitchell F.; Erath, Jessey; Tanghe, Scott; Leed, Susan E.; Rodriguez, Ana; Mensa-Wilmot, Kojo; Sciotti, Richard J.; Pollastri, Michael P. published an article.Category: pyrimidines The title of the article was Corrigendum to “Optimization of physicochemical properties for 4-Anilinoquinazoline inhibitors of trypanosome proliferation” [Eur. J. Med. Chem. 141 (2017) 446-459] [Erratum to document cited in CA167:595582]. And the article contained the following:

In the original publication, the acknowledgments section has information omitted; the correction is provided here. The experimental process involved the reaction of 4-(2-Bromopyrimidin-4-yl)morpholine(cas: 1209459-32-4).Category: pyrimidines

The Article related to anilinoquinazoline trypanosome inhibitor antimalarial malaria trypanosomiasis trypanosomicide erratum, Placeholder for records without volume info and other aspects.Category: pyrimidines

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On May 8, 2020, Yan, Tzu-Hsien; Lin, Yi-Hsin; Huang, Chao-Wei published a patent.Related Products of 160377-42-4 The title of the patent was Compound with pyridine ring, synthetic method and application as light-emitting element. And the patent contained the following:

The invention disclosed a kind of pyridine containing compound, its preparation method and application as light-emitting element in OLED. The claimed compound is shown in structure I (ring A and the ring B = (un)substituted pyridine ring; A1,A2 = same or different organic groups; R1,R2 = same or different substituent groups; m,n = 0, 1, 2 or 3). The claimed compound is prepared via coupling etc. multiple steps (procedure given). The prepared compound can be applied as electron transport layer material with good electron mobility. The experimental process involved the reaction of 5-(4-Bromophenyl)pyrimidine(cas: 160377-42-4).Related Products of 160377-42-4

The Article related to pyridine derivative preparation coupling electron transport oled, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Related Products of 160377-42-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On July 31, 1980, Iddon, Brian; Mack, Arthur G.; Suschitzky, Hans; Taylor, Jack A.; Wakefield, Basil J. published an article.Related Products of 63931-21-5 The title of the article was Polyhaloaromatic compounds. Part 42. Carbon-13 NMR spectra of polyhalopyridines and 2-pyrimidines. And the article contained the following:

13C NMR spectra are reported for 103 polyhalopyridines and 8 polyhalopyrimidines. Substituent effects were calculated and the results used to assign structures. The experimental process involved the reaction of 5-Bromo-2,4,6-trichloropyrimidine(cas: 63931-21-5).Related Products of 63931-21-5

The Article related to carbon nmr polyhalo pyridine pyrimidine, substituent effect nmr halopyridine, Physical Organic Chemistry: Spectral and Related Studies and other aspects.Related Products of 63931-21-5

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On March 1, 1994, Brown, George R.; Mallion, Keith B.; Whittamore, Paul R. O.; Brittain, David R. published a patent.Recommanded Product: 160377-42-4 The title of the patent was Quinuclidine derivatives useful as squalene synthase inhibitors and their preparation. And the patent contained the following:

Compounds of formula I and their pharmaceutically acceptable salts [R1 = H, OH; R2 = H; or R1R2 = bond; X = CH2CH2, CH:CH, CC, CH2O, CH2NH, NHCH2, CH2CO, COCH2, CH2S and SCH2; Ar1 = (un)substituted phenylene; Ar2 = (un)substituted heteroaryl; substituent(s) on Ar1 and Ar2 = halo, OH, (di)(alkyl)amino, NO2, cyano, CO2H, (di)(alkyl)carbamoyl, alkyl, alkenyl, alkynyl, alkoxy, alkoxycarbonyl, alkylthio, alkylsulfinyl, alkylsulfonyl, haloalkyl, carboxyalkyl, alkanoylamino; provided that when R1 = OH, X ≠ NHCH2 or SCH2] are inhibitors of squalene synthase, and hence useful in treating hypercholesterolemia and atherosclerosis. Possible antifungal use is also mentioned (no data). Processes for preparing I and pharmaceutical compositions containing them are also described. For example, coupling of 3-ethynyl-3-hydroxyquinuclidine with 2-(4-bromophenyl)pyridine (preparations given) using Pd(PPh3)2Cl2, CuI, and Et3N in DMF at 90°, gave title compound II. At 2.5 μM, II gave about 98% inhibition of squalene synthase in vitro; it also inhibited cholesterol biosynthesis in rats at an ED50 of 8 mg/kg (route unspecified). The experimental process involved the reaction of 5-(4-Bromophenyl)pyrimidine(cas: 160377-42-4).Recommanded Product: 160377-42-4

The Article related to quinuclidine preparation squalene synthase inhibitor, antihypercholesterolemic quinuclidine preparation, antiatherosclerotic quinuclidine preparation, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Recommanded Product: 160377-42-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On July 14, 2017, Zhang, Zhaochao; Tang, Dandan; Li, Chong published a patent.Reference of 5-(4-Bromophenyl)pyrimidine The title of the patent was Organic compound based on triazine and benzimidazole as core and application in organic electroluminescence device. And the patent contained the following:

The invention disclosed a kind of organic compound based on triazine and benzimidazole as core, its preparation method and application in organic electroluminescence device. The claimed compound is shown in structure I (x = 1 or 2; z = 1 or 2; m,n = 0, 1, or 2, and m+n+z = 3; Ar1,Ar2,Ar3 = C1-10 alkyl, or halogen atom, protium, deuterium, tritium substituted or unsubstituted Ph, naphthyl, di-Ph or pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, dibenzofuran, etc.; R1 = C1-10 alkyl, or halogen atom, protium, deuterium, tritium substituted or unsubstituted Ph, naphthyl, etc.; R2,R3 = (un)substituted benzoimidazoyl). The claimed compound is prepared via coupling etc. multiple steps (procedure given). The prepared compound has higher glass transition temperature and mol. thermal stability, low absorption and high refractive index in visible light field, and light extraction efficiency of OLED device can be effectively improved after the compound is applied to the CPL layer of OLED device. The prepared compound also has deep HOMO energy level and high electron mobility, and can be used as hole blocking / electron transport layer material for OLED device to effectively block hole or energy from being transmitted to the electron layer side from the luminescent layer, thus improving recombination efficiency of hole and electron in the luminescent layer so as to improve luminous efficiency and service life of OLED device. The experimental process involved the reaction of 5-(4-Bromophenyl)pyrimidine(cas: 160377-42-4).Reference of 5-(4-Bromophenyl)pyrimidine

The Article related to triazine benzimidazole based core derivative preparation coupling green oled, Heterocyclic Compounds (More Than One Hetero Atom): Triazines and other aspects.Reference of 5-(4-Bromophenyl)pyrimidine

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia